Drug intelligence / Profile preview

MaiLi

Development stage
Unknown
Lead developer
Sinclair
Modality
Small Molecules
Administration
Intracutaneous, Subdermal
01

Overview

MaiLi is a portfolio of premium hyaluronic acid (HA) dermal fillers developed by Sinclair Pharma (a subsidiary of Huadong Medicine). The product line includes four variants—Precise, Define, Volume, and Extreme—each designed with specific HA concentrations and rheological properties for applications ranging from fine line correction to deep facial volume restoration. Utilizing proprietary OxiFree™ technology and Smart Spring Science, the fillers create a supple, spring-like gel that integrates into the dermis to provide natural-looking results and maintain facial expression. All formulations include 0.3% lidocaine to enhance patient comfort during the injection process. MaiLi is CE-marked for the treatment of facial wrinkles, lip enhancement, volume restoration, and HIV-related lipoatrophy.

Brand names
MaiLiMaiLi PreciseMaiLi DefineMaiLi VolumeMaiLi Extreme
Other names
MaiLi HA filler
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on MaiLi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaiLi.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call